Anti-PLD4 Antibody Selective B Cell Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively regulate activated B cells, which contribute to autoimmune and allergic diseases, as existing treatments often suppress both naive and activated B cells, leading to undesirable immune system imbalances.
Innovation Solution
Development of anti-PLD4 monoclonal antibodies that specifically bind to phospholipase D4 (PLD4), targeting activated B cells to suppress their activity without affecting naive B cells, thereby preventing or treating autoimmune and allergic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional B cell suppression methods are used, then autoimmune and allergic disease symptoms are reduced, but immune system balance is disrupted by suppressing both naive and activated B cells
Solution Approach 1:
The invention targets PLD4 specifically expressed on activated B cells, segmenting the therapeutic action to affect only activated B cells while leaving naive B cells untouched. This selective targeting resolves the contradiction by achieving disease control without disrupting overall immune balance.
Solution Approach 2:
The antibody mediates selective suppression of activated B cells through PLD4 binding, creating local quality differentiation where only activated B cells are affected. This allows effective disease treatment while preserving the functional integrity of the broader immune system.
2Quantity of substance
If existing B cell suppressing treatments are administered, then antibody production is reduced, but differentiation between activated and naive B cells is lost
Solution Approach 1:
The therapy segments B cell populations by targeting PLD4 expression patterns, reducing antibody production from activated B cells while preserving naive B cell populations. This enables precise discrimination between activated and naive states through selective molecular targeting.
Solution Approach 2:
The invention exploits parameter changes in PLD4 expression levels and patterns that differentiate activated from naive B cells. By targeting this specific molecular parameter, the therapy achieves precise discrimination and selective suppression based on activation state.
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The present application provides the medicaments comprising the antibodies binding to phospholipase D4 (PLD4 ) as well as a method using said medicaments for detecting and suppressing activated B cells. The present application is further directed to therapy of auto-immune diseases and allergosis, resulting from the active-repressing function. In order to solves these problems, the present application provides that a monoclonal antibody binding to the extracellular domain of phospholipase D4 (PLD4) protein, or a fragment containing an antigen-binding region thereof as an active ingredient.